



PATENT  
ATTORNEY DOCKET NO. 50412/008001

Certificate of Mailing: Date of Deposit: October 1, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Flora Katsikis

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Larsen, et al.

Confirmation No.: 5316

Serial No.: 09/341,590

Art Unit: 1654

Filed: July 12, 1999

Examiner: Lukton, D.

Customer No.: 21559

Title: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING  
A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PETITION TO CORRECT FILING RECEIPT

Applicants request that the enclosed filing receipt be corrected as follows.

The foreign application priority info should cite, "Denmark 0317/98 Filed March 9, 1998.

Enclosed are copies of the incorrect filing receipt (with corrections marked thereon) and a copy of a certified copy of Foreign Priority Application which indicates the priority application is Denmark 0317/98 Filed March 9, 1998.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date:

October 1, 2007

Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,108

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/341,590	07/13/99	1711	\$870.00	PPT-20479-US	0	39	9

CHERYL H AGRIS  
PO BOX 806  
PELHAM NY 10803

JAN 20 1999

C Agris

OCT 03 2007  
O I P E  
P A T E N T & T R A D E M A R K O F F I C E

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice," the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) BJORNE DUE LARSEN, BRONSHOJ, DENMARK.

CONTINUING DATA AS CLAIMED BY APPLICANT-  
THIS APPLN IS A 371 OF PCT/DK99/00118 03/09/99

03/09/98

FOREIGN APPLICATIONS- DENMARK 0317/98 ~~03/09/99~~

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 01/13/00 \*\* SMALL ENTITY \*\*  
TITLE  
PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY  
TOWARDS ENZYMATIC HYDROLYSIS

PRELIMINARY CLASS: 530

DATA ENTRY BY: NGUYEN, SON

TEAM: 11 DATE: 01/13/00



(See reverse for new important information)

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE ---- The Following Information about the Filing Receipt:**

The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

The words "new," "improved," "improvement," "improvements in or relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement.

The title may be truncated if it consists of more than 4 lines of 70 characters each (letters and spaces combined).

The inventor information may be truncated if the family name consists of more than 25 characters (letters and spaces combined) and if the given name consists of more than 25 characters (letters and spaces combined). The inventor's residence allows for up to 40 characters (letters and spaces combined).

The docket number allows a maximum of 12 characters.

If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Customer Address may have been modified to conform to U.S. Postal rules.

Please direct correction, including a copy of your Filing Receipt, to:

Assistant Commissioner for Patents

Office of Initial Patent Examination

Customer Service Center

Washington, DC 20231

MAY 17 2001

TECH CENTER 1600/290



# Kongeriget Danmark

Patent application No.: 0317/98

Date of filing: 09 March 1998

Applicant:  
Bjarne Due Larsen  
Arildsgård 5, 1.th.  
DK-2700 Brønshøj

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following document:

- The specification and claims as filed with the application on the filing date indicated above.



Patent- og  
Varemærkestyrelsen  
Erhvervsministeriet



Taastrup 23 March 2001

  
Karin Schlichting  
Head Clerk